Published in Cancer Res on September 01, 2006
Angiogenesis modulates adipogenesis and obesity. J Clin Invest (2007) 3.23
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis (2009) 2.15
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol (2012) 1.96
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res (2010) 1.90
An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol (2009) 1.80
How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer. J Thyroid Res (2011) 1.46
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience. PLoS One (2014) 1.43
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol (2011) 1.19
Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res (2012) 1.19
Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther (2012) 1.05
Axitinib for the management of metastatic renal cell carcinoma. Drugs R D (2011) 1.01
Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist (2010) 1.00
Sphingosine kinase activity is not required for tumor cell viability. PLoS One (2013) 0.99
Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug Resistance. Cancers (Basel) (2014) 0.95
New therapies for dedifferentiated papillary thyroid cancer. Int J Mol Sci (2015) 0.94
Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem Pharmacol (2014) 0.93
Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci (2013) 0.93
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol (2010) 0.92
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene (2015) 0.92
Thyroid cancer: pathogenesis and targeted therapy. Ther Adv Endocrinol Metab (2011) 0.91
Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Drug Des Devel Ther (2014) 0.90
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer (2011) 0.89
Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther (2013) 0.88
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther (2011) 0.87
Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br J Cancer (2008) 0.87
Thyroid cancer: current molecular perspectives. J Oncol (2010) 0.87
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. Oncologist (2015) 0.86
Vascular endothelial growth factor pathway. Pharmacogenet Genomics (2010) 0.86
Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets (2012) 0.86
Multikinase inhibitors use in differentiated thyroid carcinoma. Biologics (2014) 0.86
In pursuit of new anti-angiogenic therapies for cancer treatment. Front Biosci (Landmark Ed) (2011) 0.85
Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives. World J Gastroenterol (2008) 0.85
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapy. Clin Cancer Res (2014) 0.84
Advanced medullary thyroid cancer: pathophysiology and management. Cancer Manag Res (2013) 0.83
New targeted molecular therapies for dedifferentiated thyroid cancer. J Oncol (2010) 0.83
Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer (2012) 0.82
Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol (2013) 0.81
A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget (2014) 0.81
Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Invest New Drugs (2008) 0.81
Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs (2011) 0.81
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib. Biologics (2014) 0.81
Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. J Exp Clin Cancer Res (2010) 0.80
Mechanisms and Targets Involved in Dissemination of Ovarian Cancer. Cancer Genomics Proteomics (2016) 0.80
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 0.79
Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol (2011) 0.79
Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors. Clin Cancer Res (2010) 0.79
Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. Sci Rep (2014) 0.78
Turning the tide in lung cancer. Nat Biotechnol (2010) 0.78
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. Ther Clin Risk Manag (2011) 0.77
Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. Onco Targets Ther (2014) 0.77
Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res (2011) 0.77
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther (2016) 0.77
Targeting angiogenesis for treatment of human cancer. Indian J Pharm Sci (2013) 0.76
Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer. J Oncol (2011) 0.76
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer. Breast Cancer Res Treat (2012) 0.76
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. Transl Lung Cancer Res (2016) 0.75
Platelet derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. Saudi J Ophthalmol (2015) 0.75
Insights into molecular therapy of glioma: current challenges and next generation blueprint. Acta Pharmacol Sin (2017) 0.75
Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors. Theranostics (2017) 0.75
Antiangiogenic effects of topically administered multiple kinase inhibitor, motesanib (AMG 706), on experimental choroidal neovascularization in mice. J Ocul Pharmacol Ther (2015) 0.75
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab (2017) 0.75
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med (2009) 4.11
Regulation of the p300 HAT domain via a novel activation loop. Nat Struct Mol Biol (2004) 3.70
Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol (2010) 3.38
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos (2003) 3.33
An effective PSO-based memetic algorithm for flow shop scheduling. IEEE Trans Syst Man Cybern B Cybern (2007) 3.30
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell (2013) 3.13
The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature (2008) 2.83
Severe fever with thrombocytopenia syndrome virus, Shandong Province, China. Emerg Infect Dis (2012) 2.77
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell (2004) 2.71
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
Usefulness of cell counter-based parameters and formulas in detection of beta-thalassemia trait in areas of high prevalence. Am J Clin Pathol (2007) 2.43
Early use of noninvasive positive pressure ventilation for acute lung injury: a multicenter randomized controlled trial. Crit Care Med (2012) 2.43
Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A (2003) 2.40
A network model to predict the risk of death in sickle cell disease. Blood (2007) 2.39
Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am J Med (2012) 2.19
TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell (2011) 2.13
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int J Cancer (2002) 2.12
Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res (2006) 2.12
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood (2009) 2.04
Clinicopathological significance of microRNA-31, -143 and -145 expression in colorectal cancer. Dis Markers (2009) 2.02
Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med (2014) 2.01
S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res (2011) 1.98
Effect of otitis media with effusion and its clinical intervention on the development of mastoid in children. Acta Otolaryngol (2014) 1.98
The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol (2003) 1.97
Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther (2010) 1.94
Effect of different labor forces on fetal skull molding. Med Eng Phys (2011) 1.92
Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res (2010) 1.90
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol (2007) 1.89
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res (2012) 1.89
(5-Bromo-2-meth-oxy-phen-yl)(4-ethyl-cyclo-hex-yl)methanone. Acta Crystallogr Sect E Struct Rep Online (2011) 1.88
Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol (2009) 1.87
Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells. Blood (2010) 1.84
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. Blood (2006) 1.83
Deletion of the laminin alpha4 chain leads to impaired microvessel maturation. Mol Cell Biol (2002) 1.81
Retracted Intragastric exposure to titanium dioxide nanoparticles induced nephrotoxicity in mice, assessed by physiological and gene expression modifications. Part Fibre Toxicol (2013) 1.80
Chinese authors do need CONSORT: reporting quality assessment for five leading Chinese medical journals. Contemp Clin Trials (2008) 1.80
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res (2006) 1.79
Antiangiogenic properties of gold nanoparticles. Clin Cancer Res (2005) 1.78
The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. Endocrinology (2005) 1.78
VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO J (2005) 1.63
Clinical and communication skills. BMJ (2005) 1.62
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest (2002) 1.57
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res (2010) 1.56
Analysing complete genome sequence of swine hepatitis E virus (HEV), strain CHN-XJ-SW13 isolated from Xinjiang, China: putative host range, and disease severity determinants in HEV. Infect Genet Evol (2011) 1.54
Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog (2009) 1.53
Heparan sulfate chains of perlecan are indispensable in the lens capsule but not in the kidney. EMBO J (2003) 1.53
Pro-inflammatory cytokine network in peripheral inflammation response to cerebral ischemia. Neurosci Lett (2013) 1.52
Neurotoxicity and gene-expressed profile in brain-injured mice caused by exposure to titanium dioxide nanoparticles. J Biomed Mater Res A (2013) 1.52
Molecular mechanism of titanium dioxide nanoparticles-induced oxidative injury in the brain of mice. Chemosphere (2013) 1.51
Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol (2006) 1.51
Highly variable chloroplast markers for evaluating plant phylogeny at low taxonomic levels and for DNA barcoding. PLoS One (2012) 1.49
Clinical and epidemiological study on severe fever with thrombocytopenia syndrome in Yiyuan County, Shandong Province, China. Am J Trop Med Hyg (2013) 1.49
Involvement of PhoP-PhoS homologs in Enterococcus faecalis virulence. Infect Immun (2002) 1.46
Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res (2002) 1.44
Coronectomy practice. Paper 1. Technique and trouble-shooting. Br J Oral Maxillofac Surg (2012) 1.44
Live three-dimensional transthoracic echocardiographic assessment of left atrial tumors. Echocardiography (2005) 1.43
Vascular endothelial growth factor and semaphorin induce neuropilin-1 endocytosis via separate pathways. Circ Res (2008) 1.43
The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax (2007) 1.41
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther (2009) 1.39
Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Bioorg Med Chem Lett (2007) 1.39
Using biofunctional magnetic nanoparticles to capture vancomycin-resistant enterococci and other gram-positive bacteria at ultralow concentration. J Am Chem Soc (2003) 1.39
N-glycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology (2007) 1.37
Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell (2005) 1.37
Melanoma-associated antigen genes - an update. Cancer Lett (2010) 1.36
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem (2007) 1.34
Accumulation of foam cells in liver X receptor-deficient mice. Circulation (2002) 1.34
Snrk-1 is involved in multiple steps of angioblast development and acts via notch signaling pathway in artery-vein specification in vertebrates. Blood (2008) 1.32
Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc Natl Acad Sci U S A (2003) 1.32
Heparan sulfate of perlecan is involved in glomerular filtration. J Am Soc Nephrol (2005) 1.28
Assessment of the quality of reporting in abstracts of randomized controlled trials published in five leading Chinese medical journals. PLoS One (2010) 1.27
Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther (2010) 1.27